---
title: "Rapport Therapeutics Q2 FY26 net loss widens to $56.6 million; R&D expense more than doubled to $51.4 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294957118.md"
description: "Rapport Therapeutics reported a widened Q2 FY26 net loss of $56.6 million, up from $26.7 million prior year, driven by R&D expenses doubling to $51.4 million. SG&A costs rose 38% to $9.4 million. Cash reserves decreased to $436.1 million, with runway extending into late 2029. The company initiated Phase 3 trials for its RAP-219 focal onset seizures program and expects bipolar mania Phase 2 data in October 2026."
datetime: "2026-08-05T11:18:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294957118.md)
  - [en](https://longbridge.com/en/news/294957118.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294957118.md)
---

# Rapport Therapeutics Q2 FY26 net loss widens to $56.6 million; R&D expense more than doubled to $51.4 million

-   Rapport Therapeutics posted a Q2 2026 net loss of $56.6 million, widening from $26.7 million a year earlier. \* R&D expense more than doubled to $51.4 million, driven by higher clinical-development and pipeline progression costs. \* SG&A rose 38.24% to $9.4 million on costs tied to business growth. \* Cash, cash equivalents and short-term investments fell to $436.1 million; runway projected into the second half of 2029. \* RAP-219 Phase 3 focal onset seizures program started, with FOCUS 1 and FOCUS 2 enrolling; bipolar mania Phase 2 topline data expected in October 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rapport Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-333853), on August 05, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [RAPP.US](https://longbridge.com/en/quote/RAPP.US.md)

## Related News & Research

- [Rapport Therapeutics CEO Abraham Ceesay sells 51,499 shares worth $2.41 million](https://longbridge.com/en/news/295706967.md)
- [Renaissance Technologies LLC Sells 109,114 Shares of Rapport Therapeutics, Inc. $RAPP](https://longbridge.com/en/news/296325369.md)
- [Pelthos Therapeutics announces annual shareholder meeting](https://longbridge.com/en/news/296270309.md)
- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)